SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

03 Nov 2022 Evaluate
The quarter ended September 2022 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 8372.30 millions.The Net Profit of the company registered a slight decline of -15.07% to Rs. 1671.80  millions from Rs. 1968.50 millions.Operating Profit reported a sharp decline to 2391.00 millions from 2852.60 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 8372.30 8237.10 1.64 16875.20 15664.30 7.73 31406.40 27185.90 15.52
Other Income 783.70 524.10 49.53 1137.90 834.10 36.42 1397.30 1035.70 34.91
PBIDT 2391.00 2852.60 -16.18 4608.30 5492.80 -16.10 10306.20 10204.80 0.99
Interest 7.10 0.70 914.29 13.40 12.40 8.06 91.20 69.00 32.17
PBDT 2383.90 2851.90 -16.41 4594.90 5480.40 -16.16 10215.00 10135.80 0.78
Depreciation 318.00 304.00 4.61 625.50 601.60 3.97 1209.60 1114.90 8.49
PBT 2065.90 2547.90 -18.92 3969.40 4878.80 -18.64 9005.40 9020.90 -0.17
TAX 394.10 579.40 -31.98 793.90 975.70 -18.63 1806.80 2264.50 -20.21
Deferred Tax -61.10 30.80 -298.38 -79.40 63.40 -225.24 95.10 97.70 -2.66
PAT 1671.80 1968.50 -15.07 3175.50 3903.10 -18.64 7198.60 6756.40 6.54
Equity 257.10 173.90 47.84 257.10 173.90 47.84 171.70 173.90 -1.27
PBIDTM(%) 28.56 34.63 -17.54 27.31 35.07 -22.12 32.82 37.54 -12.58

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×